诊断学理论与实践 ›› 2023, Vol. 22 ›› Issue (03): 209-214.doi: 10.16150/j.1671-2870.2023.03.01
收稿日期:
2023-05-10
出版日期:
2023-06-25
发布日期:
2023-11-17
通讯作者:
潘萌 E-mail:基金资助:
Received:
2023-05-10
Online:
2023-06-25
Published:
2023-11-17
摘要:
天疱疮是一类罕见的自身免疫性大疱性皮肤病,具有慢性、易复发性的特征。我国天疱疮的诊治现状存在如下问题。一,早期诊断困难,常漏诊或被误诊为湿疹、脂溢性皮炎、白塞病等,患者从发病就诊至明确诊断通常延迟数月至数年;二,患者对疾病的认知不足,天疱疮患者教育存在缺口,患者接受治疗依从性不足,自行快速减药或停药引起复发的情况屡见不鲜,常导致再次治疗的敏感性下降和不良反应发生率上升;三,医师对治疗相关不良反应的管理欠缺,部分基层医院仍使用远大于疾病控制需要剂量的激素作为天疱疮的初始治疗,并存在不规范联合用药情况。2020年1月,中国医疗保健国际交流促进会皮肤科分会发布了《寻常型天疱疮诊断和治疗专家建议(2020)》,更新了我国天疱疮的诊治规范。2021年4月,中国自身免疫性大疱病协作网正式成立,旨在以多中心、多学科协作研究推动天疱疮诊疗的进一步更新。做到“早期诊断、及时治疗、精心护理、长期随访”是天疱疮诊治的原则。本文总结我国临床的天疱疮诊治现状,对比介绍国内外天疱疮诊疗的差异,并对未来发展提出思考。
中图分类号:
潘萌, 王晶莹. 中国天疱疮的诊治现状及思考[J]. 诊断学理论与实践, 2023, 22(03): 209-214.
PAN Meng, WANG Jingying. Current status and considerations on the diagnosis and treatment of pemphigus in China[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(03): 209-214.
[1] |
SCHMIDT E, KASPERKIEWICZ M, JOLY P. Pemphigus[J]. Lancet, 2019, 394(10201):882-894.
doi: S0140-6736(19)31778-7 pmid: 31498102 |
[2] |
ZHAO L, CHEN Y, WANG M. The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis[J]. Dermatology, 2023, 239(4):514-522.
doi: 10.1159/000530121 URL |
[3] |
KRIDIN K. Pemphigus group: overview, epidemiology, mortality, and comorbidities[J]. Immunol Res, 2018, 66(2):255-270.
doi: 10.1007/s12026-018-8986-7 pmid: 29479654 |
[4] |
YUAN H, ZHOU S, LIU Z, et al. Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis[J]. J Invest Dermatol, 2017, 137(11):2362-2370.
doi: S0022-202X(17)31664-0 pmid: 28647348 |
[5] |
ZHOU S, LIU Z, YUAN H, et al. Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions[J]. J Invest Dermatol, 2020, 140(2):309-318,e8.
doi: S0022-202X(19)33203-8 pmid: 31476317 |
[6] |
ZOU Y, YUAN H, ZHOU S, et al. The pathogenic role of cd4+ tissue-resident memory T cells bearing t follicular helper-like phenotype in pemphigus lesions[J]. J Invest Dermatol, 2021, 141(9):2141-2150.
doi: 10.1016/j.jid.2021.01.030 URL |
[7] |
HOLSTEIN J, SOLIMANI F, BAUM C, et al. Immunophenotyping in pemphigus reveals a TH17/TFH17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production[J]. J Allergy Clin Immunol, 2021, 147(6):2358-2369.
doi: 10.1016/j.jaci.2020.11.008 URL |
[8] |
SASCHENBRECKER S, KARL I, KOMOROWSKI L, et al. Serological diagnosis of autoimmune bullous skin di-seases[J]. Front Immunol, 2019, 10:1974.
doi: 10.3389/fimmu.2019.01974 URL |
[9] |
GOEBELER M, BATA-CSÖRGŐ Z, DE SIMONE C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase Ⅱmulticentre, open-label feasibility trial[J]. Br J Dermatol, 2022, 186(3):429-439.
doi: 10.1111/bjd.v186.3 URL |
[10] |
YAMAGAMI J. B-cell targeted therapy of pemphigus[J]. J Dermatol, 2023, 50(2):124-131.
doi: 10.1111/jde.v50.2 URL |
[11] |
MURRELL D F, PATSATSI A, STAVROPOULOS P, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase Ⅱ BELIEVE study[J]. Br J Dermatol, 2021, 185(4):745-755.
doi: 10.1111/bjd.v185.4 URL |
[12] |
YAMAGAMI J, UJIIE H, AOYAMA Y, et al. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus[J]. J Dermatol Sci, 2021, 103(3):135-142.
doi: 10.1016/j.jdermsci.2021.07.002 pmid: 34376340 |
[13] |
ELLEBRECHT C T, BHOJ V G, NACE A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science, 2016, 353(6295):179-184.
doi: 10.1126/science.aaf6756 pmid: 27365313 |
[14] | 严汝帆, 廖洁月, 郭子瑜, 等. 天疱疮发病机制和靶向治疗的研究进展[J/OL]. 中华皮肤科杂志. 2022[2023-07-10]. http://www.pifukezazhi.com/CN/10.35541/cjd.20210248. |
YAN R F, LIAO J Y, GUO Z Y, et al. Pathogenesis and targeted therapy of pemphigus[J/OL]. Chin J Dermatol, 2022[2023-07-10]. http://www.pifukezazhi.com/CN/10.35541/cjd.20210248. | |
[15] | 中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议(2020)[J]. 中华皮肤科杂志, 2020, 53(1):1-7. |
Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. Diagnosis and treatment of pemphigus vulgaris: an expert proposal (2020)[J]. Chin J Dermatol, 2020, 53(1):1-7. | |
[16] |
JOLY P, HORVATH B, PATSATSI Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2020, 34(9):1900-1913.
doi: 10.1111/jdv.v34.9 URL |
[17] |
PORRO A M, HANS FILHO G, SANTI C G. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian So-ciety of Dermatology[J]. An Bras Dermatol, 2019, 94(2 Suppl 1):20-32.
doi: 10.1590/abd1806-4841.2019940206 URL |
[18] |
MURRELL D F, PEÑA S, JOLY P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts[J]. J Am Acad Dermatol, 2020, 82(3):575-585.e1.
doi: S0190-9622(18)30207-X pmid: 29438767 |
[19] |
CHU C Y, LEE C H, LEE H E, et al. Taiwanese dermatological association (TDA) consensus for the management of pemphigus[J]. J Formos Med Assoc, 2023, 122(7):540-548.
doi: 10.1016/j.jfma.2022.12.005 URL |
[20] | 潘萌, 郑捷. 寻常型天疱疮自身抗体检测及治疗方法的进展[J]. 中华皮肤科杂志, 2018, 51(1):5-9. |
PAN M, ZHENG J. Detection of autoantibodies in and therapeutic methods of pemphigus vulgaris[J]. Chin J Dermatol, 2018, 51(1):5-9. | |
[21] | BALIGHI K, ASHTAR NAKHAEI N, DANESHPAZHOOH M, et al. Pemphigus patients with initial negative levels of anti-desmoglein: A subtype with different profile?[J]. Dermatol Ther, 2022, 35(4):e15299. |
[22] |
SHIMIZU T, TAKEBAYASHI T, SATO Y, et al. Grading criteria for disease severity by pemphigus disease area index[J]. J Dermatol, 2014, 41(11):969-973.
doi: 10.1111/jde.2014.41.issue-11 URL |
[23] |
BOULARD C, DUVERT LEHEMBRE S, PICARD-DAHAN C, et al. Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus[J]. Br J Dermatol, 2016, 175(1):142-149.
doi: 10.1111/bjd.14405 pmid: 26800395 |
[24] | 陈喜雪, 朱学骏. 天疱疮及大疱性类天疱疮的治疗[J]. 继续医学教育, 2006, 20(23):54-56. |
CHEN X X, ZHU X J. Therapy of pmphigus and bullous pemphigoid[J]. Contin Med Educ, 2006, 20(23):54-56. | |
[25] | 赵珲, 杨宝琦. 药物超敏综合征的遗传易感性研究进展[J]. 中国麻风皮肤病杂志, 2017, 33(10):627-630. |
ZHAO H, YANG B Q. Update of genetic susceptibility of drug-induced hypersensitivity syndrome[J]. Chin J Lepr Skin Dis, 2017, 33(10):627-630. | |
[26] |
CHU C Y, LEE C H, LEE H E, et al. Taiwanese dermatological association (TDA) consensus for the management of pemphigus[J]. J Formos Med Assoc. 2023; 122(7):540-548.
doi: 10.1016/j.jfma.2022.12.005 URL |
[27] |
WERTH V P, JOLY P, MIMOUNI D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris[J]. N Engl J Med, 2021, 384(24):2295-2305.
doi: 10.1056/NEJMoa2028564 URL |
[28] |
CHEN D M, ODUEYUNGBO A, CSINADY E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect[J]. Br J Dermatol, 2020, 182(5):1111-1119.
doi: 10.1111/bjd.18482 pmid: 31487383 |
[29] |
WANG M, GAO Y, PENG Y, et al. Yearly reduction of glucocorticoid dose by 50% as tapering schedule achieves complete remission for 124 pemphigus vulgaris patients[J]. J Dermatol, 2016, 43(3):325-328.
doi: 10.1111/jde.2016.43.issue-3 URL |
[30] |
WANG M, LI J, SHANG P, et al. Evaluation of clinical factors and outcome of systemic glucocorticoid therapy discontinuation in patients with pemphigus achieving complete remission[J]. J Dermatol, 2023, 50(10):1347-1352.
doi: 10.1111/jde.v50.10 URL |
[31] | ABASQ C, MOUQUET H, GILBERT D, et al. ELISA tes-ting of anti-desmoglein 1 and 3 antibodies in the mana-gement of pemphigus[J]. Arch Dermatol, 2009, 145(5):529-535. |
[1] | 乌心怡, 潘萌, 朱海琴. 自身免疫性大疱性皮肤病的实验室诊断进展[J]. 诊断学理论与实践, 2023, 22(03): 306-310. |
[2] | 王麒钧, 朱海琴, 潘萌. 天疱疮主要自身抗体及其检测临床意义研究进展[J]. 诊断学理论与实践, 2022, 21(05): 638-643. |
[3] | 魏玉珠, 吴涛, 毛军峰, 胡晓燕, 武慧敏, 白海, 王存邦. 以颈椎病变首诊的弥漫大B细胞淋巴瘤一例报道[J]. 诊断学理论与实践, 2017, 16(04): 432-433. |
[4] | 王文方, 徐子真, 王爱华, 诸江, 李军民,. 利妥昔单抗和RAD001对弥漫大B细胞株SUDHL-4和DB细胞增殖和凋亡的影响[J]. 诊断学理论与实践, 2012, 11(02): 130-135. |
[5] | 殷凯生,. 难治性哮喘诊治中的若干问题[J]. 诊断学理论与实践, 2006, 5(02): 183-186. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||